Ianalumab, which has already succeeded in testing against Sjogren’s syndrome, proved impactful in a condition that causes low ...
A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight ...
In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback